Search clinical trials for: Empagliflozin 25 MG

Total 11323 results

Instituto Nacional de Cardiologia Ignacio Chavez

Not yet recruiting

Empagliflozin for No-reflow Phenomenon in PCI for STEMI (EMPA-PCI)

STEMI | No-Reflow Phenomenon
Centro Universitario de Ciencias de la Salud, Mexico

Active, not recruiting

Acute Effect of Empagliflozin vs Dapagliflozin Over Pulse Wave Velocity in Type Two Diabetes

Diabetes Mellitus Type 2 Without Complication

Mexico
University of Sao Paulo General Hospital

Recruiting

iSGLT2 in Prevention of Acute Kidney Injury in Patients With Diabetes Mellitus Undergoing CABG Extracorporeal On-Pump (POST-CABGDM)

Coronary Artery Disease | Diabetes Mellitus, Type 2 | Acute Kidney Injury | Coronary Artery Bypass Surgery

Brazil
Boehringer Ingelheim
Eli Lilly and Company

Completed

Linagliptin as Add on Therapy to Empagliflozin 10 mg or 25 mg With Japanese Patients With Type 2 Diabetes Mellitus

Diabetes Mellitus, Type 2

Japan
National Taiwan University Hospital
Shin Kong Wu Ho-Su Memorial Hospital

Not yet recruiting

EMPAgliflozin in Heart Failure With PReserved Ejection Fraction and End Stage Renal Disease (EMPA-PRED)

Heart Failure With Preserved Ejection Fraction | End Stage Renal Disease on Dialysis
Amsterdam UMC, location VUmc

Completed

SGLT2 Inhibition: Uric Acid Excretion Study (UREX)

Type 2 Diabetes

Netherlands
Damanhour University

Recruiting

Sodium-glucose Transport 2 Inhibitors (SGLT2i) in HFrEF Patients

Heart Failure | Reduced Ejection Fraction Heart Failure

Egypt
University of Mississippi Medical Center
Eli Lilly and Company

Recruiting

Empagliflozin in ESKD - A Feasibility Study

Heart Failure | Kidney Failure, Chronic

United States
University Health Network, Toronto

Recruiting

Incretin and Treatment With Inhibition of Sodium-glucose Cotransporter-2 Combination Insights Into Mechanisms Implicated in Congestive Heart Failure: "NATRIURETIC" Trial (NATRIURETIC)

Type 2 Diabetes Mellitus

Canada
Dong-A ST Co., Ltd.

Completed

Pharmacokinetic and Pharmacodynamic Drug-Drug Interaction of Evogliptin and Empagliflozin or Dapagliflozin in Healthy Male Adults

Type2 Diabetes

Korea, Republic of
Yale University
Boehringer Ingelheim

Recruiting

Effect of Empagliflozin on Peritoneal and Kidney Function in End Stage Renal Disease (EMPA-PD)

End Stage Renal Disease on Dialysis

United States
Tanta University

Active, not recruiting

Empagliflozin in Treatment of Peripheral Diabetic Neuropathy

Diabetic Neuropathy Peripheral

Egypt
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Completed

Bioequivalence Study of Empagliflozin Tablet in Healthy Participants.

Type 2 Diabetes

China
Boehringer Ingelheim

Completed

Long-term Safety and Efficacy of Empagliflozin as Add on to GLP-1 RA

Diabetes Mellitus, Type 2

Japan
The University of Texas Health Science Center at...
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); Doris...

Recruiting

SGLT2 Inhibitors, Ketones, and Cardiovascular Benefit Research Plan

Type2 Diabetes | Heart Failure With Preserved Ejection Fraction

United States
University of Virginia
National Heart, Lung, and Blood Institute (NHLBI)

Recruiting

Effects of Empagliflozin on Cardiac Microvasculature and Insulin Sensitivity in Subjects With Type 2 Diabetes (EJB051)

Type2 Diabetes | Insulin Sensitivity

United States
Medical University of Warsaw
Medical University of Graz; Medical University of Vienna; Poznan University of... and other collaborators

Recruiting

Empagliflozin and Dapagliflozin in Patients Hospitalized for Acute Decompensated Heart Failure (EMPATHY)

Acute Decompensated Heart Failure

Poland
University of Sao Paulo

Completed

Effect of Empagliflozin on Ventricular Repolarization. (EMPATHYHEART)

Diabetes Mellitus, Type 2 | Coronary Heart Disease | Arrythmia, Cardiac

Brazil
Vanderbilt University Medical Center

Completed

SGLT2 Inhibitor Effects on Inflammation and Heart Disease in Obesity Pilot

Obesity | Pre-diabetes

United States
Isfahan University of Medical Sciences

Completed

Antiischemic Effects of Empagliflozin in Diabetic Patients With Refractory Angina

Diabetes Mellitus

Iran, Islamic Republic of
Steno Diabetes Center Copenhagen
Novo Nordisk A/S

Unknown

Renal Effects of Treatment With Empagliflozin Alone or in Combination With Semaglutide in Patients With Type 2 Diabetes and Albuminuria (EmpaSema)

Type 2 Diabetes With Renal Manifestations

Denmark
Shahid Beheshti University of Medical Sciences

Recruiting

Effects of Empagliflozin in Reducing Oxidative Stress After Kidney Transplantation

Kidney Transplant; Complications

Iran, Islamic Republic of
University Hospital, Basel, Switzerland
Centre Hospitalier Universitaire Vaudois; Luzerner Kantonsspital

Recruiting

Effects of the SGLT2 Inhibitor Empagliflozin in Patients With Euvolemic and Hypervolemic Hyponatremia (EMPOWER)

Liver Failure | Hyponatremia | Kidney Failure | SIADH

Switzerland
University Hospital Inselspital, Berne

Completed

Investigating the Impact of the SGLT2 Inhibitor Empagliflozin on Postprandial Hypoglycaemia After Gastric Bypass

Dumping Syndrome | Hypoglycemia, Reactive

Switzerland
University Hospital Inselspital, Berne
Boehringer Ingelheim; University of Bern

Completed

Impact of the SGLT2 Inhibitor Empagliflozin on Urinary Supersaturations in Kidney Stone Formers (SWEETSTONE)

Kidney Stone

Switzerland
National Institute on Aging (NIA)

Completed

Sodium-glucose Co Transporter 2 (sGLT2) Inhibitor and Endogenous Ketone Production

Physiological Effects of Drugs | Hypoglycemic Agents | Empaglifozin | Sodium-Glucose Transporter 2 Inhibitors

United States
Boehringer Ingelheim
Eli Lilly and Company

Completed

Relative Bioavailability of 2 Fixed Dose Combinations of Empagliflozin/Metformin Compared With Single Tablets

Healthy

United States
Karolinska Institutet
Karolinska University Hospital

Recruiting

Adipose Tissue Heterogeneity and Its Link to Type 2 Diabetes (DiaSpax)

Type 2 Diabetes

Sweden
University Health Network, Toronto

Not yet recruiting

meChANisms and sAfety of SGLT2 Inhibition in peRitoneal dialYsis (CANARY)

End Stage Kidney Disease | Kidney Dysfunction | Peritoneal Dialysis Complication | Sodium-glucose Co-transporter-2 Inhibitors | Residual Kidney Function

Canada
The University of Texas Health Science Center at...
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Active, not recruiting

Empagliflozin and Hepatic Glucose Metabolism

Hepatic Glucose Metabolism

United States
The University of Texas Health Science Center at...
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Recruiting

SGLT2 Inhibitors, Ketogenesis, and Ketoacidosis

Type 1 Diabetes | Type 2 Diabetes

United States
Omar Tarek Elfarargi

Not yet recruiting

Comparison Between the Efficacy of SGLT2 Inhibitor Therapy Versus ACE Inhibitor in the Treatment of Diabetic Kidney Disease (SGLT2i VS ACEi)

Diabetic Nephropathy Type 2
Vanderbilt University Medical Center

Recruiting

The Effect of SGLT2 Inhibition on Adipose Inflammation and Endothelial Function (SADIE2)

Obesity | Metabolic Syndrome

United States
Washington University School of Medicine

Recruiting

Sodium-Glucose Cotransporter-2 Inhibitors: A Potential Novel Treatment for Epilepsy

Epilepsy

United States
Boehringer Ingelheim
Eli Lilly and Company

Completed

Bioavailability of Empagliflozin/Metformin Fixed Dose Combinations (FDCs) in Healthy Chinese Volunteers

Healthy

China
Christian Schulze
Boehringer Ingelheim; Zentrum für Klinische Studien Jena

Completed

Effects of Empagliflozin on Diuresis and Renal Function in Patients With Acute Decompensated Heart Failure (EMPAG-HF)

Acute Decompensated Heart Failure

Germany
Boehringer Ingelheim

Completed

Drug Drug Interaction of Empagliflozin (BI 10773) and Warfarin in Healthy Volunteers

Healthy

Germany
Kasr El Aini Hospital

Completed

Empagliflozin in Patients With Glomerulonephritis

Proteinuria | Glomerulonephritis

Egypt
Ain Shams University

Not yet recruiting

Assessment of Safety and Efficacy of SGLT2is Among LN Patients

Lupus Nephritis

Egypt
International Bio service

Not yet recruiting

Bioequivalence Study of Empagliflozin 25 mg Film-coated Tablets in Healthy Thai Volunteers

Healthy Volunteer
Fayoum University
Cairo University

Not yet recruiting

SGLT2 Inhibitors Prophylaxis Against Post-contrast Acute Kidney Injury in Diabetic Kidney Disease?

SGLT2i Kideny Protection Against Contrast in Diabetic Kidney
University of Sao Paulo General Hospital

Recruiting

SGLT-2 Inhibitors in Prevention of Post-procedural Renal and Cardiovascular Complications aFter PCI Among Patients With Diabetes Mellitus and Coronary Artery Disease: a Prospective, Randomized, Pilot Study (SAFE-PCI) (SAFE-PCI)

Coronary Artery Disease | Diabetes Mellitus, Type 2 | Acute Kidney Injury

Brazil
McGill University Health Centre/Research Institute...

Recruiting

Empagliflozin in Acute Heart Failure (DRIP-AHF-1)

Chronic Kidney Diseases | Acute Heart Failure

Canada
Chungbuk National University Hospital

Active, not recruiting

Empagliflozin-based Quadruple Therapy vs Basal Insulin-based Therapy (LUCID)

Diabetes Mellitus, Type 2
National University of Malaysia

Unknown

Effect of SGLT2 Inhibition on OCT-A Parameters in Diabetic CKD

Diabetes Mellitus | Chronic Kidney Diseases | Diabetic Retinopathy

Malaysia
Zydus Lifesciences Limited

Active, not recruiting

Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ZYIL1 in Patients With Amyotrophic Lateral Sclerosis

Amyotrophic Lateral Sclerosis

India
ViiV Healthcare
GlaxoSmithKline; Janssen Pharmaceuticals

Completed

Relative Oral Bioavailability Study of Different Fixed Dose Combinations of Dolutegravir and Rilpivirine in Healthy Subjects

Infection, Human Immunodeficiency Virus

United States
National Taiwan University Hospital
Shin Kong Wu Ho-Su Memorial Hospital

Not yet recruiting

Empagliflozin in Heart Failure With Reduced Ejection Fraction and End Stage Renal Disease (EMPA-RRED)

Heart Failure With Reduced Ejection Fraction | End Stage Renal Disease on Dialysis
Centre Hospitalier Universitaire Vaudois
University College, London; Great Ormond Street Hospital for Children NHS Foundation...

Not yet recruiting

Repurposing Empagliflozin and Dapagliflozin for Paediatric Heart Failure: Translational Approach and Dose Rationale

Heart Failure

Switzerland, United Kingdom
The University of Texas Health Science Center at...
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Recruiting

Ketones, SGLT2, HFrEF

Heart Failure With Reduced Ejection Fraction | Type2diabetes

United States

Search clinical trials for: Empagliflozin 25 MG

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Mexico

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations